Ylitalo N, Josefsson A, Melbye M, Sörensen P, Frisch M, Andersen P K, Sparén P, Gustafsson M, Magnusson P, Pontén J, Gyllensten U, Adami H O
Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden.
Cancer Res. 2000 Nov 1;60(21):6027-32.
Human papillomavirus 16 (HPV16) is a predominant cause of cervical neoplasia. However, no population-based study with long-term follow-up has clarified the temporal relationship between HPV16 infection and occurrence of carcinoma in situ, or the importance of recurrent or persistent infection. This nested case-control study was carried out in a population-based cohort of women participating in cytological screening whose initial smear, taken in 1969-1995, was normal. During up to 26 years of follow-up, carcinoma in situ was diagnosed in 484 eligible women. Archival smears from these women were compared with smears from 619 individually matched controls. After DNA extraction, a highly sensitive PCR system was used to detect HPV16. Among case women, the prevalence of HPV16 positivity was 56% at the time of diagnosis. The relative risk of cervical carcinoma in situ increased from 3.6 (95% confidence interval, 1.2-11.0) 13 years before diagnosis to 11.1 (95% confidence interval, 5.5-22.2) 1 year before diagnosis. Having a positive smear at entry to the cohort increased risk >5-fold, whereas having persistent infection with HPV in two subsequent smears increased risk 30-fold. We estimated that among HPV16-positive women, the median incubation period from infection to carcinoma in situ was 7-12 years. We conclude that evidence of persistent and/or recurrent infection is associated with a drastically higher risk of cervical carcinoma in situ than occasional infection with HPV16.
人乳头瘤病毒16型(HPV16)是宫颈癌前病变的主要病因。然而,尚无一项基于人群的长期随访研究阐明HPV16感染与原位癌发生之间的时间关系,或反复感染或持续感染的重要性。这项巢式病例对照研究在一组参与细胞学筛查的女性人群队列中开展,这些女性在1969年至1995年进行的首次涂片检查结果正常。在长达26年的随访期间,484名符合条件的女性被诊断为原位癌。将这些女性的存档涂片与619名个体匹配对照的涂片进行比较。提取DNA后,使用高灵敏度PCR系统检测HPV16。在病例女性中,诊断时HPV16阳性率为56%。原位宫颈癌的相对风险从诊断前13年的3.6(95%置信区间,1.2 - 11.0)增加到诊断前1年的11.1(95%置信区间,5.5 - 22.2)。队列入组时涂片阳性使风险增加超过5倍,而在随后的两次涂片中持续感染HPV使风险增加30倍。我们估计,在HPV16阳性女性中,从感染到原位癌的中位潜伏期为7至12年。我们得出结论,与偶尔感染HPV16相比,持续和/或反复感染的证据与原位宫颈癌的风险大幅升高相关。